Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia

Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16.

Abstract

Introduction: Central venous catheters (CVC) related thrombosis (CRT) represents a well known complication in patients with acute myeloid leukemia (AML) receiving intensive chemotherapy but the efficacy of antithrombotic prophylaxis still remains controversial.

Patients and methods: We analyzed 71 consecutive AML patients whose CVC was inserted before each chemotherapy cycle for an overall number of 106 CVC placements. In 47/106 insertions, a prophylaxis with 100 IU/kg/day low molecular weight heparin (LMWH) was administered for 7 days after CVC insertion and additional 7 after CVC removal. This unconventional dose of LMWH, although higher than usual, appeared adequate for a short-course approach. LMWH was delivered regardless of the platelet (PLT) count once provided that it should have been maintained above 20 x 10(9)/L by transfusions.

Results: Of 106 insertions, we observed 19 (18%) episodes of CRT, 58 (54%) of sepsis and 50 (47%) infections of CVC-exit site with no difference between LMWH and no-LMWH group. Occurrence of CRT was significantly associated with CVC-exit site infections (14/19, p=0.01) and sepsis (16/19, p=0.005) with no difference between LMWH and no-LMWH group. In multivariate analysis, both CVC-exit site infections and sepsis were confirmed to be independent risk factors for CRT development.

Conclusion: Our retrospective study, although based on a small sample size, suggests that the occurrence of CVC-exit site infections and neutropenic sepsis following chemotherapy significantly increases the risk of CRT in AML, independently from the use of LMWH prophylaxis.

Keywords: AML; Acute myeloid leukemia; CRT; CVC; Catheters-related thrombosis; Central venous catheters; Central venous catheters related thrombosis; DVT; Exit-site infection; G-CSF; Heparin prophylaxis; LMWH; MTHFR; PE; PICC; PLT; PN; SVC; Sepsis; TF; Thrombocytopenia; VTE; WBC; acute myeloid leukemia; deep vein thrombosis; granulocyte cell stimulating factors; low molecular weight heparin; methylentetrahydrofolatereductase; non-tunneled subclavian venous catheter; parenteral nutrition; peripherally inserted central-venous catheter; platelet; pulmonary embolism; tissue factor; venous thromboembolism; white blood cell.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / complications*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Sepsis / complications
  • Upper Extremity Deep Vein Thrombosis / etiology*
  • Upper Extremity Deep Vein Thrombosis / prevention & control*
  • Young Adult

Substances

  • Anticoagulants
  • Antineoplastic Agents
  • Heparin, Low-Molecular-Weight